{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:57:49Z","timestamp":1789012669785,"version":"build-2803163510"},"reference-count":27,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T00:00:00Z","timestamp":1591228800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004622","name":"Dutch Cancer Society","doi-asserted-by":"publisher","award":["EMCR 2014-6998"],"award-info":[{"award-number":["EMCR 2014-6998"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.tranon.2020.100817","type":"journal-article","created":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T12:20:53Z","timestamp":1592482853000},"page":"100817","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Ibrutinib is not an effective drug in primografts of TCF3-PBX1"],"prefix":"10.1016","volume":"13","author":[{"given":"Cesca","family":"van de Ven","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Boeree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Femke","family":"Stalpers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Michel","family":"Zwaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique L.","family":"Den Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tranon.2020.100817_bb0005","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1200\/JCO.2010.30.7405","article-title":"Biology, risk stratification, and therapy of pediatric acute leukemias: an update","volume":"29","author":"Pui","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2020.100817_bb0010","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/gcc.20431","article-title":"Molecular cytogenetic characterization of TCF3 (E2A)\/19p13.3 rearrangements in B-cell precursor acute lymphoblastic leukemia","volume":"46","author":"Barber","year":"2007","journal-title":"Genes Chromosom. Cancer"},{"key":"10.1016\/j.tranon.2020.100817_bb0015","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/bjh.15056","article-title":"A risk score including microdeletions improves relapse prediction for standard and medium risk precursor B-cell acute lymphoblastic leukaemia in children","volume":"180","author":"Sutton","year":"2018","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.tranon.2020.100817_bb0020","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1200\/JCO.2015.64.6364","article-title":"Successful therapy reduction and intensification for childhood acute lymphoblastic leukemia based on minimal residual disease monitoring: study ALL10 from the Dutch childhood oncology group","volume":"34","author":"Pieters","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2020.100817_bb0025","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.pcl.2014.09.006","article-title":"Treatment of pediatric acute lymphoblastic leukemia","volume":"62","author":"Cooper","year":"2015","journal-title":"Pediatr. Clin. N. Am."},{"key":"10.1016\/j.tranon.2020.100817_bb0030","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1586\/ehm.11.8","article-title":"Adverse effects of treatment in childhood acute lymphoblastic leukemia: general overview and implications for long-term cardiac health","volume":"4","author":"Ness","year":"2011","journal-title":"Expert. Rev. Hematol."},{"key":"10.1016\/j.tranon.2020.100817_bb0035","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2141.2011.08824.x","article-title":"Paediatric B-cell precursor acute lymphoblastic leukaemia with t(1;19)(q23;p13): clinical and cytogenetic characteristics of 47 cases from the Nordic countries treated according to NOPHO protocols","volume":"155","author":"Andersen","year":"2011","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.tranon.2020.100817_bb0040","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.3324\/haematol.11239","article-title":"Incidence and outcome of TCF3-PBX1-positive acute lymphoblastic leukemia in Austrian children","volume":"92","author":"Kager","year":"2007","journal-title":"Haematologica."},{"key":"10.1016\/j.tranon.2020.100817_bb0045","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/cam4.221","article-title":"Outcome of TCF3-PBX1 positive pediatric acute lymphoblastic leukemia patients in Japan: a collaborative study of Japan Association of Childhood Leukemia Study (JACLS) and Children's Cancer and Leukemia Study Group (CCLSG)","volume":"3","author":"Asai","year":"2014","journal-title":"Cancer Med."},{"key":"10.1016\/j.tranon.2020.100817_bb0050","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1038\/leu.2009.42","article-title":"Increased risk for CNS relapse in pre-B cell leukemia with the t(1;19)\/TCF3-PBX1","volume":"23","author":"Jeha","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.tranon.2020.100817_bb0055","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1182\/blood-2016-03-704973","article-title":"Integration of genetic and clinical risk factors improves prognostication in relapsed childhood B-cell precursor acute lymphoblastic leukemia","volume":"128","author":"Irving","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2020.100817_bb0060","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2014.5","article-title":"Interference with pre-B-cell receptor signaling offers a therapeutic option for TCF3-rearranged childhood acute lymphoblastic leukemia","volume":"4","author":"van der Veer","year":"2014","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.tranon.2020.100817_bb0065","doi-asserted-by":"crossref","first-page":"8557","DOI":"10.1074\/jbc.M008886200","article-title":"Expression and regulation of normal and polymorphic epithelial sodium channel by human lymphocytes","volume":"276","author":"Bubien","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tranon.2020.100817_bb0070","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1600-065X.2000.imr017504.x","article-title":"The role of Bruton's tyrosine kinase in B-cell development and function: a genetic perspective","volume":"175","author":"Satterthwaite","year":"2000","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.tranon.2020.100817_bb0075","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy","volume":"107","author":"Honigberg","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tranon.2020.100817_bb0080","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.cellsig.2012.09.008","article-title":"BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-kappaB","volume":"25","author":"Rushworth","year":"2013","journal-title":"Cell. Signal."},{"key":"10.1016\/j.tranon.2020.100817_bb0085","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies","volume":"31","author":"Advani","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2020.100817_bb0090","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1182\/blood-2011-10-386417","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo","volume":"119","author":"Ponader","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2020.100817_bb0095","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1182\/blood-2014-10-606038","article-title":"Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib","volume":"125","author":"Byrd","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2020.100817_bb0100","doi-asserted-by":"crossref","first-page":"4618","DOI":"10.18632\/oncotarget.13492","article-title":"Tyrosine kinase fusion genes in pediatric BCR-ABL1-like acute lymphoblastic leukemia","volume":"8","author":"Boer","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.tranon.2020.100817_bb0105","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1038\/sj.leu.2405033","article-title":"Fusion of ZMIZ1 to ABL1 in a B-cell acute lymphoblastic leukaemia with a t(9;10)(q34;q22.3) translocation","volume":"22","author":"Soler","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.tranon.2020.100817_bb0110","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1470-2045(08)70339-5","article-title":"A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study","volume":"10","author":"Den Boer","year":"2009","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.tranon.2020.100817_bb0115","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/bjc.1991.333","article-title":"In vitro drug sensitivity of normal peripheral blood lymphocytes and childhood leukaemic cells from bone marrow and peripheral blood","volume":"64","author":"Kaspers","year":"1991","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.tranon.2020.100817_bb0120","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tranon.2020.100817_bb0125","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ccell.2015.02.003","article-title":"Self-enforcing feedback activation between BCL6 and pre-B cell receptor signaling defines a distinct subtype of acute lymphoblastic leukemia","volume":"27","author":"Geng","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.tranon.2020.100817_bb0130","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1182\/blood-2016-06-722900","article-title":"Ibrutinib inhibits pre-BCR(+) B-cell acute lymphoblastic leukemia progression by targeting BTK and BLK","volume":"129","author":"Kim","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2020.100817_bb0135","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1182\/blood-2011-11-390989","article-title":"The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia","volume":"119","author":"de Rooij","year":"2012","journal-title":"Blood"}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523320303090?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523320303090?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T14:40:14Z","timestamp":1761835214000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523320303090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S1936523320303090"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2020.100817","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ibrutinib is not an effective drug in primografts of TCF3-PBX1","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2020.100817","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Inc. on behalf of Neoplasia Press, Inc.","name":"copyright","label":"Copyright"}],"article-number":"100817"}}